FindTrial
Sign In

JNJ-70218902

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMetastatic Castration-resistant Prostate Cancer (mCRPC)Myelodysplastic SyndromesNeoplasmsSolid Tumor, Adult

Phase 1

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
CompletedNCT04397276
Janssen Research & Development, LLCNeoplasms
Start: 2020-07-10End: 2025-09-16Updated: 2026-02-17
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Enrolling by invitationNCT06788509
Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4
Start: 2024-12-30End: 2028-01-21Target: 80Updated: 2025-10-10

Related Papers

1360 Pharmacodynamics of JNJ-70218902, a TMEFF2 × CD3 bispecific antibody, in cynomolgus monkey
Regular and Young Investigator Award Abstracts2022-11-01
Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models
Cancer Research2022-06-151 citations